Biogen Inc [BIIB] stock is trading at $132.2, up 0.19%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BIIB shares have gain 2.26% over the last week, with a monthly amount drifted -0.50%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, HSBC Securities downgraded its rating to Hold on April 28, 2025, and kept the price target unchanged to $118. On April 04, 2025, downgrade downgraded it’s rating to Hold. Bernstein started tracking the stock assigning a Mkt Perform rating and suggested a price target of $160 on February 11, 2025. Piper Sandler downgraded its rating to a Neutral and reduced its price target to $138 on January 02, 2025. BMO Capital Markets downgraded its rating to Market Perform for this stock on December 20, 2024, and downed its price target to $164. In a note dated December 16, 2024, Stifel downgraded an Hold rating on this stock but restated the target price of $175.
Biogen Inc [BIIB] stock has fluctuated between $110.04 and $213.50 over the past year. Currently, Wall Street analysts expect the stock to reach $197.88 within the next 12 months. Biogen Inc [NASDAQ: BIIB] shares were valued at $132.2 at the most recent close of the market. An investor can expect a potential return of 49.68% based on the average BIIB price forecast.
Analyzing the BIIB fundamentals
Biogen Inc [NASDAQ:BIIB] reported sales of 9.61B for the trailing twelve months, which represents a growth of 8.86%. Gross Profit Margin for this corporation currently stands at 0.55% with Operating Profit Margin at 0.16%, Pretax Profit Margin comes in at 0.18%, and Net Profit Margin reading is 0.15%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.09 and Total Capital is 0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.37.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Biogen Inc’s Current Ratio is 2.50. As well, the Quick Ratio is 1.79, while the Cash Ratio is 0.87. Considering the valuation of this stock, the price to sales ratio is 2.02, the price to book ratio is 1.10 and price to earnings (TTM) ratio is 12.65.
Transactions by insiders
Recent insider trading involved Izzar Rachid, Head of Global Product Strat., that happened on Jul 08 ’25 when 2223.0 shares were sold. Officer, Izzar Rachid completed a deal on Jul 08 ’25 to buy 2223.0 shares. Meanwhile, Head of Development Singhal Priya sold 3806.0 shares on May 19 ’25.
